Summary
Global Markets Direct’s, ‘Traumatic Brain Injury - Pipeline Review, H2 2016’, provides an overview of the Traumatic Brain Injury pipeline landscape.
The report provides comprehensive information on the therapeutics under development for Traumatic Brain Injury, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Traumatic Brain Injury and features dormant and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.
Scope
- The report provides a snapshot of the global therapeutic landscape of Traumatic Brain Injury
- The report reviews pipeline therapeutics for Traumatic Brain Injury by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Traumatic Brain Injury therapeutics and enlists all their major and minor projects
- The report assesses Traumatic Brain Injury therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Traumatic Brain Injury
Reasons to buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Traumatic Brain Injury
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Traumatic Brain Injury pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Companies Mentioned
ALSP, Inc.
Amarantus Bioscience Holdings, Inc.
Athersys, Inc.
Beech Tree Labs, Inc.
Cognosci, Inc.
Euroscreen S.A.
Intellect Neurosciences, Inc.
Ischemix, Inc.
Karyopharm Therapeutics, Inc.
Kyorin Pharmaceutical Co., Ltd.
Levolta Pharmaceuticals, Inc.
Lixte Biotechnology Holdings, Inc.
Lpath, Inc.
MandalMed, Inc.
Mapreg S.A.S.
Neuralstem, Inc.
Neuren Pharmaceuticals Limited
NeuroNascent, Inc.
Neuronax SAS
NeuroVive Pharmaceutical AB
New World Laboratories, Inc.
Novogen Limited
NuvOx Pharma LLC
Omeros Corporation
PharmatrophiX, Inc.
Phylogica Limited
Prevacus, Inc.
QR Pharma, Inc.
RegeneRx Biopharmaceuticals, Inc.
Remedy Pharmaceuticals, Inc.
Sage Therapeutics, Inc.
SanBio, Inc.
STATegics, Inc.
Stemedica Cell Technologies, Inc.
SynZyme Technologies, LLC
Tetra Discovery Partners LLC
Thera Neuropharma Inc
vasopharm GmbH
VG Life Sciences, Inc.
'
Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 8
Introduction 9
Global Markets Direct Report Coverage 9
Traumatic Brain Injury Overview 10
Therapeutics Development 11
Pipeline Products for Traumatic Brain Injury - Overview 11
Pipeline Products for Traumatic Brain Injury - Comparative Analysis 12
Traumatic Brain Injury - Therapeutics under Development by Companies 13
Traumatic Brain Injury - Therapeutics under Investigation by Universities/Institutes 17
Traumatic Brain Injury - Pipeline Products Glance 18
Clinical Stage Products 18
Early Stage Products 19
Traumatic Brain Injury - Products under Development by Companies 20
Traumatic Brain Injury - Products under Investigation by Universities/Institutes 24
Traumatic Brain Injury - Companies Involved in Therapeutics Development 25
ALSP, Inc. 25
Amarantus Bioscience Holdings, Inc. 26
Athersys, Inc. 27
Beech Tree Labs, Inc. 28
Cognosci, Inc. 29
Euroscreen S.A. 30
Intellect Neurosciences, Inc. 31
Ischemix, Inc. 32
Karyopharm Therapeutics, Inc. 33
Kyorin Pharmaceutical Co., Ltd. 34
Levolta Pharmaceuticals, Inc. 35
Lixte Biotechnology Holdings, Inc. 36
Lpath, Inc. 37
MandalMed, Inc. 38
Mapreg S.A.S. 39
Neuralstem, Inc. 40
Neuren Pharmaceuticals Limited 41
NeuroNascent, Inc. 42
Neuronax SAS 43
NeuroVive Pharmaceutical AB 44
New World Laboratories, Inc. 45
Novogen Limited 46
NuvOx Pharma LLC 47
Omeros Corporation 48
PharmatrophiX, Inc. 49
Phylogica Limited 50
Prevacus, Inc. 51
QR Pharma, Inc. 52
RegeneRx Biopharmaceuticals, Inc. 53
Remedy Pharmaceuticals, Inc. 54
Sage Therapeutics, Inc. 55
SanBio, Inc. 56
STATegics, Inc. 57
Stemedica Cell Technologies, Inc. 58
SynZyme Technologies, LLC 59
Tetra Discovery Partners LLC 60
Thera Neuropharma Inc 61
vasopharm GmbH 62
VG Life Sciences, Inc. 63
Traumatic Brain Injury - Therapeutics Assessment 64
Assessment by Monotherapy Products 64
Assessment by Combination Products 65
Assessment by Target 66
Assessment by Mechanism of Action 69
Assessment by Route of Administration 72
Assessment by Molecule Type 74
Drug Profiles 76
(levocetirizine dihydrochloride + montelukast sodium) - Drug Profile 76
2-DG - Drug Profile 77
ALP-496 - Drug Profile 78
AMRS-001 - Drug Profile 80
AST-001 - Drug Profile 89
AST-002 - Drug Profile 90
AVL-8168 - Drug Profile 91
BQ-A - Drug Profile 92
BTL-slo - Drug Profile 93
Cell Therapy for Traumatic Brain Injury - Drug Profile 94
Cell Therapy to Activate hNT-3 for Spinal Cord and Traumatic Brain Injury - Drug Profile 95
CHEC-7 - Drug Profile 96
CHEC-9 - Drug Profile 97
CMX-2043 - Drug Profile 98
CNB-001 - Drug Profile 101
COG-1410 - Drug Profile 103
cyclosporine - Drug Profile 105
dexamethasone acetate + melatonin - Drug Profile 110
EPO-Variant - Drug Profile 111
ESN-502 - Drug Profile 112
ethinyl estradiol sulfonate - Drug Profile 113
EUC-001 - Drug Profile 114
felbamate - Drug Profile 115
glyburide - Drug Profile 116
HBI-002 - Drug Profile 119
HBI-137 - Drug Profile 120
HBN-1 - Drug Profile 121
HBN-2 - Drug Profile 122
HPI-201 - Drug Profile 123
HPI-363 - Drug Profile 124
ibudilast - Drug Profile 125
ICCN-100 - Drug Profile 133
JM-4 - Drug Profile 134
KPT-350 - Drug Profile 135
LB-201 - Drug Profile 137
LB-205 - Drug Profile 138
LM-22A4 - Drug Profile 139
LM11A-31BHS - Drug Profile 141
Lpathomab - Drug Profile 143
MAP-4343 - Drug Profile 146
Monoclonal Antibody for Central Nervous System - Drug Profile 147
N-acetyl cysteine amide - Drug Profile 148
ND-478 - Drug Profile 149
Neu-2000 - Drug Profile 150
neuregulin-1 - Drug Profile 152
NNI-370 - Drug Profile 153
NNZ-2591 - Drug Profile 154
NSI-189 - Drug Profile 156
NSI-566 - Drug Profile 160
NVP-019 - Drug Profile 168
NVX-428 - Drug Profile 169
NWL-53 - Drug Profile 170
NX-210 - Drug Profile 171
PF-05285401 - Drug Profile 172
Posiphen - Drug Profile 183
PRV-002 - Drug Profile 186
PYC-35 - Drug Profile 187
PYC-36 - Drug Profile 188
PYC-38 - Drug Profile 189
PYC-98 - Drug Profile 190
R-503 - Drug Profile 191
RGN-352 - Drug Profile 193
ronopterin - Drug Profile 197
SanFlow - Drug Profile 199
SB-623 - Drug Profile 200
sepranolone - Drug Profile 204
Small Molecule to Activate Epsilon PKC for Traumatic Brain Injury - Drug Profile 211
Small Molecule to Antagonize GPR17 for Central Nervous System Disorders - Drug Profile 212
Small Molecules for Stroke and Traumatic Brain Injury - Drug Profile 213
Small Molecules for Traumatic Brain Injury - Drug Profile 214
Small Molecules to Antagonize TLR-4 for CNS Disorders - Drug Profile 215
Small Molecules to Inhibit PBR for Traumatic Brain Injury and Neurodegenerative Diseases - Drug Profile 216
Stem Cell Therapy for Cardiovascular Disease, CNS Disorders, Metabolic Disorders, Respiratory Disease, Infectious Disease and Toxicology - Drug Profile 217
Stem Cell Therapy for Central Nervous System Disorder - Drug Profile 222
Stem Cell Therapy for CNS Disorders - Drug Profile 223
STSE-15 - Drug Profile 224
SYN-2 - Drug Profile 226
SYN-NCE - Drug Profile 227
T-094 - Drug Profile 228
TauC-3 - Drug Profile 229
UH-0113 - Drug Profile 230
UH-0213 - Drug Profile 231
VG-1177 - Drug Profile 232
VitalHeme - Drug Profile 234
VOLT-02 - Drug Profile 235
ZL-006 - Drug Profile 236
Traumatic Brain Injury - Dormant Projects 237
Traumatic Brain Injury - Discontinued Products 242
Traumatic Brain Injury - Product Development Milestones 243
Featured News & Press Releases 243
Appendix 255
Methodology 255
Coverage 255
Secondary Research 255
Primary Research 255
Expert Panel Validation 255
Contact Us 255
Disclaimer 256
List of Tables
Number of Products under Development for Traumatic Brain Injury, H2 2016 17
Number of Products under Development for Traumatic Brain Injury - Comparative Analysis, H2 2016 18
Number of Products under Development by Companies, H2 2016 19
Number of Products under Development by Companies, H2 2016 (Contd..1) 20
Number of Products under Development by Companies, H2 2016 (Contd..2) 21
Number of Products under Development by Companies, H2 2016 (Contd..3) 22
Number of Products under Investigation by Universities/Institutes, H2 2016 23
Comparative Analysis by Clinical Stage Development, H2 2016 24
Comparative Analysis by Early Stage Development, H2 2016 25
Products under Development by Companies, H2 2016 26
Products under Development by Companies, H2 2016 (Contd..1) 27
Products under Development by Companies, H2 2016 (Contd..2) 28
Products under Development by Companies, H2 2016 (Contd..3) 29
Products under Investigation by Universities/Institutes, H2 2016 30
Traumatic Brain Injury - Pipeline by ALSP, Inc., H2 2016 31
Traumatic Brain Injury - Pipeline by Amarantus Bioscience Holdings, Inc., H2 2016 32
Traumatic Brain Injury - Pipeline by Athersys, Inc., H2 2016 33
Traumatic Brain Injury - Pipeline by Beech Tree Labs, Inc., H2 2016 34
Traumatic Brain Injury - Pipeline by Cognosci, Inc., H2 2016 35
Traumatic Brain Injury - Pipeline by Euroscreen S.A., H2 2016 36
Traumatic Brain Injury - Pipeline by Intellect Neurosciences, Inc., H2 2016 37
Traumatic Brain Injury - Pipeline by Ischemix, Inc., H2 2016 38
Traumatic Brain Injury - Pipeline by Karyopharm Therapeutics, Inc., H2 2016 39
Traumatic Brain Injury - Pipeline by Kyorin Pharmaceutical Co., Ltd., H2 2016 40
Traumatic Brain Injury - Pipeline by Levolta Pharmaceuticals, Inc., H2 2016 41
Traumatic Brain Injury - Pipeline by Lixte Biotechnology Holdings, Inc., H2 2016 42
Traumatic Brain Injury - Pipeline by Lpath, Inc., H2 2016 43
Traumatic Brain Injury - Pipeline by MandalMed, Inc., H2 2016 44
Traumatic Brain Injury - Pipeline by Mapreg S.A.S., H2 2016 45
Traumatic Brain Injury - Pipeline by Neuralstem, Inc., H2 2016 46
Traumatic Brain Injury - Pipeline by Neuren Pharmaceuticals Limited, H2 2016 47
Traumatic Brain Injury - Pipeline by NeuroNascent, Inc., H2 2016 48
Traumatic Brain Injury - Pipeline by Neuronax SAS, H2 2016 49
Traumatic Brain Injury - Pipeline by NeuroVive Pharmaceutical AB, H2 2016 50
Traumatic Brain Injury - Pipeline by New World Laboratories, Inc., H2 2016 51
Traumatic Brain Injury - Pipeline by Novogen Limited, H2 2016 52
Traumatic Brain Injury - Pipeline by NuvOx Pharma LLC, H2 2016 53
Traumatic Brain Injury - Pipeline by Omeros Corporation, H2 2016 54
Traumatic Brain Injury - Pipeline by PharmatrophiX, Inc., H2 2016 55
Traumatic Brain Injury - Pipeline by Phylogica Limited, H2 2016 56
Traumatic Brain Injury - Pipeline by Prevacus, Inc., H2 2016 57
Traumatic Brain Injury - Pipeline by QR Pharma, Inc., H2 2016 58
Traumatic Brain Injury - Pipeline by RegeneRx Biopharmaceuticals, Inc., H2 2016 59
Traumatic Brain Injury - Pipeline by Remedy Pharmaceuticals, Inc., H2 2016 60
Traumatic Brain Injury - Pipeline by Sage Therapeutics, Inc., H2 2016 61
Traumatic Brain Injury - Pipeline by SanBio, Inc., H2 2016 62
Traumatic Brain Injury - Pipeline by STATegics, Inc., H2 2016 63
Traumatic Brain Injury - Pipeline by Stemedica Cell Technologies, Inc., H2 2016 64
Traumatic Brain Injury - Pipeline by SynZyme Technologies, LLC, H2 2016 65
Traumatic Brain Injury - Pipeline by Tetra Discovery Partners LLC, H2 2016 66
Traumatic Brain Injury - Pipeline by Thera Neuropharma Inc, H2 2016 67
Traumatic Brain Injury - Pipeline by vasopharm GmbH, H2 2016 68
Traumatic Brain Injury - Pipeline by VG Life Sciences, Inc., H2 2016 69
Assessment by Monotherapy Products, H2 2016 70
Assessment by Combination Products, H2 2016 71
Number of Products by Stage and Target, H2 2016 73
Number of Products by Stage and Mechanism of Action, H2 2016 76
Number of Products by Stage and Route of Administration, H2 2016 79
Number of Products by Stage and Molecule Type, H2 2016 81
Traumatic Brain Injury - Dormant Projects, H2 2016 243
Traumatic Brain Injury - Dormant Projects (Contd..1), H2 2016 244
Traumatic Brain Injury - Dormant Projects (Contd..2), H2 2016 245
Traumatic Brain Injury - Dormant Projects (Contd..3), H2 2016 246
Traumatic Brain Injury - Dormant Projects (Contd..4), H2 2016 247
Traumatic Brain Injury - Discontinued Products, H2 2016 248
List of Figures
Number of Products under Development for Traumatic Brain Injury, H2 2016 17
Number of Products under Development for Traumatic Brain Injury - Comparative Analysis, H2 2016 18
Number of Products under Development by Companies, H2 2016 19
Number of Products under Investigation by Universities/Institutes, H2 2016 23
Comparative Analysis by Clinical Stage Development, H2 2016 24
Comparative Analysis by Early Stage Products, H2 2016 25
Assessment by Monotherapy Products, H2 2016 70
Number of Products by Top 10 Targets, H2 2016 72
Number of Products by Stage and Top 10 Targets, H2 2016 72
Number of Products by Top 10 Mechanism of Actions, H2 2016 75
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016 75
Number of Products by Top 10 Routes of Administration, H2 2016 78
Number of Products by Stage and Top 10 Routes of Administration, H2 2016 78
Number of Products by Molecule Types, H2 2016 80
Number of Products by Stage and Molecule Types, H2 2016 80
